🔴 Cue Biopharma is trading 6.8% down in after-hours trading with no company-specific catalyst identified

Cue Biopharma is trading at $18.50, down 6.75%, with no clear company-specific explanation identified for the November 4 decline.

• The latest surfaced company-specific news was positive CUE-221 Phase 2 results announced in September, not a fresh catalyst.
• Shares closed November 4 at $19.84, down 4.89%, as broader indexes rose; market direction does not explain the after-hours drop.
• The price context shows a reversal after November 3’s 7.42% gain; no volume data was provided.